Developer docs
API playgroundTry for free, no card

Search company profiles

AvenCell

Full company profile

uuid0000mx7

Namestring
AvenCell
Legal namestring
AvenCell Therapeutics, Inc.
Websiteurl
avencell.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic CAR-T therapy, switchable CAR-T platform, CRISPR gene editing, hematologic malignancy treatment, cell therapy biotechnology
Industry3 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Allogeneic CAR-T Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CAR-T Cell Therapy Development and Commercialization
TypeOne Time License
Description

AvenCell is developing allogeneic CAR-T cell therapy candidates for hematologic malignancies. The company aims to commercialize off-the-shelf cell therapy products that address limitations of autologous CAR-T therapies including manufacturing timelines, costs, and accessibility.

avencell.com
2Co-development and Co-funding Agreements
TypeLicensing Royalties
Description

The company has co-development and co-funding (Co-Co) agreements with Intellia Therapeutics for allogeneic universal CAR-T cell products, with Intellia having options to enter additional Co-Co agreements.

avencell.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AvenCell is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies for hard-to-treat hematologic cancers. Its pipeline combines two proprietary platforms — the Universal Switchable CAR (UniCAR/RevCAR) platform, which allows rapid on/off control of CAR-T activity through soluble Targeting Modules, and the TrueAllo allogeneic platform using CRISPR/Cas9 engineering to overcome graft-versus-host disease and host rejection. Lead candidates include AVC-201 (CD123-directed, for AML), AVC-203 (CD19/CD20 dual-targeting, for B-cell malignancies), and AVC-202 (multiple myeloma).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I proof-of-concept demonstrated efficacy signals in late-line R/R AML patients with 1 PR and 2 CRi in first 3 fully treated patients
+2 more records
Product overview1 text field

AvenCell is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies for hard-to-treat cancers. The company's portfolio consists of three clinical-stage product candidates: AVC-201 (lead allogeneic CD123-directed switchable CAR-T for AML), AVC-203 (CD19/CD20 dual-targeting CAR-T for B-cell malignancies and autoimmune diseases), and AVC-202 (undisclosed target for multiple myeloma). These therapies are built on two proprietary technology platforms: the Universal Switchable CAR platform, which enables rapid on/off control of CAR-T activity via separately infused Targeting Modules, and the TrueAllo allogeneic platform, which allows the use of healthy donor cells engineered to avoid graft-versus-host disease and rejection. The company was launched in 2021 through a partnership combining GEMoaB's switchable CAR-T technology with Intellia's CRISPR/Cas9 genome editing capabilities.

Product and service3 records
1AVC-201
CategoryClinical-stage CAR-T Cell Therapy Candidate
Description

First-in-class CRISPR-engineered allogeneic CD123-directed switchable CAR-T therapy for relapsed/refractory acute myeloid leukemia (AML) and other CD123-positive hematological malignancies. Combines Universal Switchable CAR-T technology with the TrueAllo platform to provide an off-the-shelf product engineered to overcome graft-versus-host disease and host rejection. Currently in Phase I clinical development (RevSTAR-123 study, NCT05949125).

2AVC-203
CategoryClinical-stage CAR-T Cell Therapy Candidate
Description

CRISPR-engineered allogeneic CD19/CD20 dual-targeting switchable CAR-T therapy for relapsed/refractory B-cell malignancies including DLBCL, with potential expansion into autoimmune disease indications. Built on the TrueAllo platform with improved gene editing and manufacturing processes for superior CAR-T expansion and persistence. World's first CRISPR-engineered allogeneic dual-targeting switchable CAR-T.

3AVC-202
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFounding/FlagshipTypeStrategic or Co-development PartnerAnnounced on2021-06-22
Description

Contributed switchable Universal CAR-T technology developed by GEMoaB GmbH and manufacturing expertise including GMP facilities for CAR-T cell production. GEMoaB became a subsidiary of the newly established company. Cellex is a world leader in manufacturing hematopoietic blood stem cell products and leading European manufacturer for CAR-T cells.

Strategic tierFounding/FlagshipTypeStrategic or Co-development PartnerAnnounced on2021-06-22
Description

Contributed best-in-class CRISPR/Cas9 genome editing technology creating an allogeneic universal CAR-T platform. Entered into co-development and co-funding (Co-Co) agreement to develop an allogeneic universal CAR-T product. Intellia has option to enter second Co-Co agreement for selected products. Equal ownership with Blackstone and Cellex in new company.

3GEMoaB GmbH
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-22
Description

Acquired as subsidiary of AvenCell. GEMoaB is the clinical-stage biopharmaceutical company that developed the UniCAR and RevCAR switchable universal CAR-T platforms. Continues to advance clinical stage CAR T-cell programs including GEM333 (CD33 bispecific antibody) and GEM3PSCA (PSCA bispecific antibody) partnered with Bristol-Myers Squibb.

avencell.com
4Bristol-Myers Squibb
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-06-22
Description

Global partnership through GEMoaB for Phase I assets GEM333 (CD33 bispecific antibody for AML) and GEM3PSCA (PSCA bispecific antibody for prostate cancer). Bristol-Myers Squibb acquired Celgene which had partnership agreements with GEMoaB.

avencell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-20
Description

Academic medical center collaborating on clinical trials with Prof. Gerhard Ehninger (former Head of Hematology and Oncology) and Dr. Martin Wermke as principal investigators for Phase I studies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cellectis is a clinical-stage biotech developing allogeneic CAR-T therapies using TALEN gene editing, with programs in AML, ALL, and other hematologic cancers. Highly comparable to AvenCell on allogeneic platform, gene editing foundation, and overlapping AML/B-cell target space.

TypeEmerging player
Description

Adicet Bio is a clinical-stage biotech developing allogeneic gamma-delta CAR-T cell therapies for hematologic malignancies and autoimmune diseases. Emerging allogeneic CAR-T peer with overlapping B-cell and autoimmune indications that AvenCell's AVC-203 also targets.

TypeDirect peer
Description

Atara Biotherapeutics develops allogeneic T-cell and CAR-T immunotherapies for hematologic malignancies and solid tumors, including tabelecleucel for EBV+ PTLD. Direct comparable as an allogeneic cell therapy peer focused on similar hematologic indications.

TypeOthers
Description

Intellia Therapeutics is a co-founding partner of AvenCell and the source of the CRISPR/Cas9 allogeneic platform underlying TruAllo. While not a direct CAR-T competitor (Intellia focuses on in vivo gene editing), it is the enabling technology partner whose platform underpins AvenCell's core cell engineering capability.

5Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS owns commercial autologous CAR-T therapies Breyanzi (CD19) and Abecma (BCMA) plus the partnership with GEMoaB through which AvenCell originated. Functions as both a strategic partner and broad incumbent competitor in the same hematologic CAR-T market AvenCell is targeting.

TypeDirect peer
Description

Caribou Biosciences is a clinical-stage allogeneic CAR-T developer using CRISPR-based gene editing for off-the-shelf cell therapies in hematologic malignancies. Direct comparable on platform technology (CRISPR allogeneic), target indications, and clinical-stage positioning versus AvenCell.

TypeDirect peer
Description

Allogene Therapeutics is a clinical-stage biotech pioneering allogeneic CAR-T cell therapies with multiple programs in hematologic malignancies. It is the most directly comparable peer to AvenCell given shared allogeneic platform strategy, target indications (B-cell, AML), and gene-editing-enabled off-the-shelf approach.

TypeDirect peer
Description

Precision BioSciences develops allogeneic CAR-T therapies using its proprietary ARCUS gene-editing platform for hematologic cancers. Comparable to AvenCell as a clinical-stage allogeneic CAR-T competitor targeting similar hematologic malignancy indications with gene-edited donor cells.

TypeDirect peer
Description

Fate Therapeutics develops off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSC) for cancer and autoimmune diseases. Comparable to AvenCell on the off-the-shelf cell therapy thesis for hematologic malignancies, with a distinct but adjacent allogeneic platform approach.

TypeDirect peer
Description

Crispr Therapeutics develops gene-edited allogeneic CAR-T cell therapies including the approved Casgevy (with Vertex) and multiple clinical-stage hematology programs. Highly comparable to AvenCell via shared CRISPR/Cas9 allogeneic engineering and focus on hematologic malignancies including AML and B-cell cancers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AvenCell

Allogeneic CAR-T Cell Therapyavencell.com

AvenCell firmographics

Firmographics
Name
AvenCell
Legal name
AvenCell Therapeutics, Inc.
Website
https://avencell.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

AvenCell industry classification

Industry
Product category
Allogeneic CAR-T Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Allogeneic CAR-T therapy
  • Switchable CAR-T platform
  • CRISPR gene editing
  • Hematologic malignancy treatment
  • Cell therapy biotechnology

Where AvenCell is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices4 records

Markets served

AvenCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. CAR-T Cell Therapy Development and Commercialization: AvenCell is developing allogeneic CAR-T cell therapy candidates for hematologic malignancies. The company aims to commercialize off-the-shelf cell therapy products that address limitations of autologous CAR-T therapies including manufacturing timelines, costs, and accessibility.
  2. Co-development and Co-funding Agreements: The company has co-development and co-funding (Co-Co) agreements with Intellia Therapeutics for allogeneic universal CAR-T cell products, with Intellia having options to enter additional Co-Co agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

AvenCell product offering

Product offering

Core offering

AvenCell is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies for hard-to-treat hematologic cancers. Its pipeline combines two proprietary platforms — the Universal Switchable CAR (UniCAR/RevCAR) platform, which allows rapid on/off control of CAR-T activity through soluble Targeting Modules, and the TrueAllo allogeneic platform using CRISPR/Cas9 engineering to overcome graft-versus-host disease and host rejection. Lead candidates include AVC-201 (CD123-directed, for AML), AVC-203 (CD19/CD20 dual-targeting, for B-cell malignancies), and AVC-202 (multiple myeloma).

Product overview

AvenCell is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies for hard-to-treat cancers. The company's portfolio consists of three clinical-stage product candidates: AVC-201 (lead allogeneic CD123-directed switchable CAR-T for AML), AVC-203 (CD19/CD20 dual-targeting CAR-T for B-cell malignancies and autoimmune diseases), and AVC-202 (undisclosed target for multiple myeloma). These therapies are built on two proprietary technology platforms: the Universal Switchable CAR platform, which enables rapid on/off control of CAR-T activity via separately infused Targeting Modules, and the TrueAllo allogeneic platform, which allows the use of healthy donor cells engineered to avoid graft-versus-host disease and rejection. The company was launched in 2021 through a partnership combining GEMoaB's switchable CAR-T technology with Intellia's CRISPR/Cas9 genome editing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • AVC-201 First-in-class CRISPR-engineered allogeneic CD123-directed switchable CAR-T therapy for relapsed/refractory acute myeloid leukemia (AML) and other CD123-positive hematological malignancies. Combines Universal Switchable CAR-T technology with the TrueAllo platform to provide an off-the-shelf product engineered to overcome graft-versus-host disease and host rejection. Currently in Phase I clinical development (RevSTAR-123 study, NCT05949125).
  • AVC-203 CRISPR-engineered allogeneic CD19/CD20 dual-targeting switchable CAR-T therapy for relapsed/refractory B-cell malignancies including DLBCL, with potential expansion into autoimmune disease indications. Built on the TrueAllo platform with improved gene editing and manufacturing processes for superior CAR-T expansion and persistence. World's first CRISPR-engineered allogeneic dual-targeting switchable CAR-T.
  • AVC-202

Quantifiable outcome

  • Phase I proof-of-concept demonstrated efficacy signals in late-line R/R AML patients with 1 PR and 2 CRi in first 3 fully treated patients
  • +2 more outcomes

Companies that use AvenCell

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles4 records

AvenCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AvenCell partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered founding/flagship, core and minor.

  • Cellex Cell Professionalsfounding/flagshipStrategic or Co-development Partner · 22 June 2021Contributed switchable Universal CAR-T technology developed by GEMoaB GmbH and manufacturing expertise including GMP facilities for CAR-T cell production. GEMoaB became a subsidiary of the newly established company. Cellex is a world leader in manufacturing hematopoietic blood stem cell products and leading European manufacturer for CAR-T cells.
  • Intellia Therapeuticsfounding/flagshipStrategic or Co-development Partner · 22 June 2021Contributed best-in-class CRISPR/Cas9 genome editing technology creating an allogeneic universal CAR-T platform. Entered into co-development and co-funding (Co-Co) agreement to develop an allogeneic universal CAR-T product. Intellia has option to enter second Co-Co agreement for selected products. Equal ownership with Blackstone and Cellex in new company.
  • GEMoaB GmbHcoreStrategic or Co-development Partner · 22 June 2021Acquired as subsidiary of AvenCell. GEMoaB is the clinical-stage biopharmaceutical company that developed the UniCAR and RevCAR switchable universal CAR-T platforms. Continues to advance clinical stage CAR T-cell programs including GEM333 (CD33 bispecific antibody) and GEM3PSCA (PSCA bispecific antibody) partnered with Bristol-Myers Squibb.
  • Bristol-Myers SquibbminorStrategic or Co-development Partner · 22 June 2021Global partnership through GEMoaB for Phase I assets GEM333 (CD33 bispecific antibody for AML) and GEM3PSCA (PSCA bispecific antibody for prostate cancer). Bristol-Myers Squibb acquired Celgene which had partnership agreements with GEMoaB.
  • University Hospital Carl Gustav Carus DresdencoreStrategic or Co-development Partner · 20 July 2020Academic medical center collaborating on clinical trials with Prof. Gerhard Ehninger (former Head of Hematology and Oncology) and Dr. Martin Wermke as principal investigators for Phase I studies.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

AvenCell competitors and assessment

Company assessment

Direct peers

  • Cellectis: Cellectis is a clinical-stage biotech developing allogeneic CAR-T therapies using TALEN gene editing, with programs in AML, ALL, and other hematologic cancers. Highly comparable to AvenCell on allogeneic platform, gene editing foundation, and overlapping AML/B-cell target space.
  • Atara Biotherapeutics: Atara Biotherapeutics develops allogeneic T-cell and CAR-T immunotherapies for hematologic malignancies and solid tumors, including tabelecleucel for EBV+ PTLD. Direct comparable as an allogeneic cell therapy peer focused on similar hematologic indications.
  • Caribou Biosciences: Caribou Biosciences is a clinical-stage allogeneic CAR-T developer using CRISPR-based gene editing for off-the-shelf cell therapies in hematologic malignancies. Direct comparable on platform technology (CRISPR allogeneic), target indications, and clinical-stage positioning versus AvenCell.
  • Allogene Therapeutics: Allogene Therapeutics is a clinical-stage biotech pioneering allogeneic CAR-T cell therapies with multiple programs in hematologic malignancies. It is the most directly comparable peer to AvenCell given shared allogeneic platform strategy, target indications (B-cell, AML), and gene-editing-enabled off-the-shelf approach.
  • Precision BioSciences: Precision BioSciences develops allogeneic CAR-T therapies using its proprietary ARCUS gene-editing platform for hematologic cancers. Comparable to AvenCell as a clinical-stage allogeneic CAR-T competitor targeting similar hematologic malignancy indications with gene-edited donor cells.
  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSC) for cancer and autoimmune diseases. Comparable to AvenCell on the off-the-shelf cell therapy thesis for hematologic malignancies, with a distinct but adjacent allogeneic platform approach.
  • Crispr Therapeutics: Crispr Therapeutics develops gene-edited allogeneic CAR-T cell therapies including the approved Casgevy (with Vertex) and multiple clinical-stage hematology programs. Highly comparable to AvenCell via shared CRISPR/Cas9 allogeneic engineering and focus on hematologic malignancies including AML and B-cell cancers.

Emerging players

  • Adicet Bio: Adicet Bio is a clinical-stage biotech developing allogeneic gamma-delta CAR-T cell therapies for hematologic malignancies and autoimmune diseases. Emerging allogeneic CAR-T peer with overlapping B-cell and autoimmune indications that AvenCell's AVC-203 also targets.

Others

  • Intellia Therapeutics: Intellia Therapeutics is a co-founding partner of AvenCell and the source of the CRISPR/Cas9 allogeneic platform underlying TruAllo. While not a direct CAR-T competitor (Intellia focuses on in vivo gene editing), it is the enabling technology partner whose platform underpins AvenCell's core cell engineering capability.

Broad incumbents

  • Bristol-Myers Squibb: BMS owns commercial autologous CAR-T therapies Breyanzi (CD19) and Abecma (BCMA) plus the partnership with GEMoaB through which AvenCell originated. Functions as both a strategic partner and broad incumbent competitor in the same hematologic CAR-T market AvenCell is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AvenCell social profiles

Digital presence

AvenCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AvenCell leadership team

Management profile

Number of profiles

Profiles6 records

AvenCell subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

AvenCell funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AvenCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AvenCell

What does AvenCell do?

AvenCell is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies for hard-to-treat hematologic cancers. Its pipeline combines two proprietary platforms — the Universal Switchable CAR (UniCAR/RevCAR) platform, which allows rapid on/off control of CAR-T activity through soluble Targeting Modules, and the TrueAllo allogeneic platform using CRISPR/Cas9 engineering to overcome graft-versus-host disease and host rejection. Lead candidates include AVC-201 (CD123-directed, for AML), AVC-203 (CD19/CD20 dual-targeting, for B-cell malignancies), and AVC-202 (multiple myeloma).

Is AvenCell a public or private company?

AvenCell is a private company. It is classified as venture growth investor backed and is currently operating.

When was AvenCell founded?

AvenCell was founded in 2021. It employs 51 to 100 people.

Where is AvenCell based?

AvenCell is headquartered in Cambridge, United States, in the North America region.

How does AvenCell make money?

Two revenue lines are on record. CAR-T Cell Therapy Development and Commercialization is the primary driver. The others are co-development and Co-funding Agreements.

Who are AvenCell's main competitors?

Direct peers on record are Cellectis, Atara Biotherapeutics, Caribou Biosciences, Allogene Therapeutics, Precision BioSciences, Fate Therapeutics and Crispr Therapeutics. Adicet Bio is listed as an emerging player. Intellia Therapeutics is listed as an others. Bristol-Myers Squibb is listed as a broad incumbent.

Does AvenCell have an API?

No public API is recorded for AvenCell.

What industry is AvenCell in?

AvenCell's product category is Allogeneic CAR-T Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Insider Trading & Hedge Fund DataLigand (LGND)-AvenCell Deal: Most of the Funding Is Tied to MilestonesLigand Pharmaceuticals announced a $47 million financing agreement with AvenCell Therapeutics, committing up to $6 million to Series C and $41 million to drug development, with tranches tied to clinical milestones. The deal adds potential royalty exposure to a portfolio of over 200 assets, with Q2 royalty revenue up 32% to $48 million and a 2026 target of $225–250 million.Seeking AlphaLigand, AvenCell financing deal worth up to $47M (LGND:NASDAQ)Ligand Pharmaceuticals announced a financing agreement worth up to $47M with AvenCell Therapeutics to advance AvenCell's CAR-T cell therapy pipeline. AvenCell's lead asset is AVC-201, an anti-CD123 CAR-T undergoing a Phase 1b expansion.BioSpaceAvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026AvenCell Therapeutics will present Phase 1a data from the RevSTAR-123 study of its switchable allogeneic CAR-T candidate AVC-201 in CD123-positive relapsed/refractory or MRD-positive AML at EHA 2026 in Stockholm. The study is registered as NCT05949125, and the presentation is scheduled for June 13.PR NewswireAvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026AvenCell Therapeutics announced that data from the completed Phase 1a portion of the RevSTAR-123 study evaluating its switchable allogeneic CAR-T candidate AVC-201 for CD123-positive relapsed/refractory or MRD-positive acute myeloid leukemia will be presented in a late-breaking oral plenary session at the 2026 European Hematology Association Congress in Stockholm. The study, registered as NCT05949125, will be presented by Dr. Martin Wermke from University Hospital Carl Gustav Carus Dresden. The therapy remains investigational and has not been approved by any regulatory authority.AijournAvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/RefAvenCell Therapeutics announced that the first patient has been dosed in the Phase I QUADvance study with AVC-203, a CRISPR-engineered allogeneic CAR-T therapy simultaneously targeting CD19 and CD20 receptors for relapsed/refractory B-cell malignancies. AVC-203 represents the world's first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T cell therapy to enter clinical testing. The program is supported by a $40 million grant from Japan's AMED, with planned clinical expansion to Japan and the broader Asia-Pacific region following regulatory clearances from the FDA and EMA.PR NewswireAvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/RefAvenCell Therapeutics dosed the first patient in its Phase I QUADvance study with AVC-203, a CRISPR-engineered allogeneic dual-targeting CD19/CD20 CAR-T therapy for relapsed/refractory B-cell malignancies, marking what the company calls the world's first such therapy to enter clinical testing. The trial received FDA IND clearance and EMA CTA approval in late 2025 and is being conducted at multiple sites in the US and Europe with planned expansion to Japan, supported by a $40 million grant from Japan's AMED. The company stated this milestone builds on its existing allogeneic CAR-T program in AML and aims to address limitations of approved autologous CAR-T therapies including manufacturing timelines, costs, and accessibility.PR NewswireAvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T InAvenCell Therapeutics announced that the FDA and European Medicines Agency have cleared its Investigational New Drug application and approved its Clinical Trial Application for the QUADvance study. This Phase I/II trial will evaluate AVC-203, a CRISPR-engineered allogeneic CAR-T therapy targeting B-cell malignancies, across sites in the US and Europe.YahooViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood CancersViroCell Biologics successfully delivered a retroviral vector to AvenCell Therapeutics for manufacturing its allogeneic CAR-T therapy AVC-203. The vector will support a first-in-human phase I study in relapsed/refractory B cell lymphoma in H2/2025. The collaboration aims to accelerate clinical entry for the dual-targeted cell therapy.citybizBioCryst Appoints Babar Ghias Chief Financial OfficerBioCryst Pharmaceuticals has appointed Babar Ghias as its new chief financial officer and head of corporate development, effective immediately. Ghias joins from AvenCell Therapeutics, bringing extensive experience in capital raising and operational leadership from previous roles at Paragon Biosciences and Marathon Pharmaceuticals.PR NewswireAvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T ProgramAvenCell Japan received up to $40 million from AMED to advance its AVC203 allogeneic CAR-T therapy for B-cell lymphomas. The dual-antigen (CD19 & CD20) IND-stage candidate uses gene editing to prevent immune rejection. Early data from AVC201 show robust expansion beyond typical allogeneic rejection hurdles.